Rational design of small molecules able to inhibit α-synuclein amyloid aggregation for the treatment of Parkinson’s disease

Serena Vittorio*, Ilenia Adornato, Rosaria Gitto, Samuel Peña-Díaz, Salvador Ventura, Laura De Luca*

*Autor corresponent d’aquest treball

Producció científica: Contribució a una revistaArticleRecercaAvaluat per experts

19 Cites (Scopus)

Resum

Parkinson’s disease is one of the most common neurodegenerative disorders in elderly age. One of the mechanisms involved in the neurodegeneration appears related to the aggregation of the presynaptic protein alpha synuclein (α-syn) into toxic oligomers and fibrils. To date, no highly effective treatment is currently available; therefore, there is an increasing interest in the search of new therapeutic tools. The modulation of α-syn aggregation represents an emergent and promising disease-modifying strategy for reducing or blocking the neurodegenerative process. Herein, by combining in silico and in vitro screenings we initially identified 3-(cinnamylsulfanyl)-5-(4-pyridinyl)-1,2,4-triazol-4-amine (3) as α-syn aggregation inhibitor that was then considered a promising hit for the further design of a new series of small molecules. Therefore, we rationally designed new hit-derivatives that were synthesised and evaluated by biological assays. Lastly, the binding mode of the newer inhibitors was predicted by docking studies.

Idioma originalEnglish
Pàgines (de-a)1727-1735
Nombre de pàgines9
RevistaJournal of Enzyme Inhibition
Volum35
Número1
DOIs
Estat de la publicacióPublicada - 1 de gen. 2020

Fingerprint

Navegar pels temes de recerca de 'Rational design of small molecules able to inhibit α-synuclein amyloid aggregation for the treatment of Parkinson’s disease'. Junts formen un fingerprint únic.

Com citar-ho